Afonso P, Brissos S, Figueira ML, Paiva T (2010) Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr Res 120(1–3):227–228

Afonso P, Brissos S, Figueira ML, Paiva T (2011a) Schizophrenia patients with predominantly positive symptoms have more disturbed sleep-wake cycles measured by actigraphy. Psychiatry Res 189(1):62–66

Afonso P, Figueira ML, Paiva T (2011b) Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. Int J Psychiatry Clin Pract 15(4):311–315

Alonso-Vale MI, Peres SB, Vernochet C, Farmer SR, Lima FB (2009) Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. J Pineal Res 47(3):221–227

Anderson G (2011) Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 76(1):54–60

Anderson G, Ojalla J (2010) Alzheimer’s and seizures: interleukin-18, indoleamine 2,3-Dioxygenase and quinolinic acid. Int J Tryp Res 3:169–173

Aufdenblatten M, Baumann M, Raio L, Dick B, Frey BM, Schneider H, Surbek D, Hocher B, Mohaupt MG (2009) Prematurity is related to high placental cortisol in preeclampsia. Pediatr Res 65(2):198–202

Aversa S, Pellegrino S, Barberi I, Reiter RJ, Gitto E (2012) Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. J Matern-Fetal Neonatal Med 25(3):207–221

Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M (2003) Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett 24(3–4):181–184

Bikle DD (2009) Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep 7(2):58–63

Bošković M, Vovk T, Kores Plesničar B, Grabnar I (2011) Oxidative stress in schizophrenia. Curr Neuropharmacol 9(2):301–312

Brown AS, Derkitis EJ (2010) Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 167(3):261–280

Bushe CJ, Leonard BE (2007) Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 68(11):1682–1690

Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB (2007) Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 97(1–3):51–59

Cantó C, Auwerx J (2009) Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab 20(7):325–331

Causevic M, Mohaupt M (2007) 11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia. Mol Aspects Med 28(2):220–226

Chang HM, Wu UI, Lan CT (2009) Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res 47(3):211–220

Chun RF, Adams JS, Hewison M (2008) Review: Back to the future: a new look at “old” vitamin D3. J Endocrinol 198:261–269

Chwastiak LA, Tek C (2009) The unchanging mortality gap for people with schizophrenia. Lancet 374(9690):590–592

Condray R, Dougherty GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK (2011) 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 14:756–767

Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA, van Beverens NJM, Drexhage HA (2011) An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 14:746–755

Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8(3):228–242

Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, Hewison M (2006) Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod 75(6):816–822

Flaum M (2010) Strategies to close the “mortality gap”. Am J Psychiatry 167(2):120–121

Graham SM, Howgate D, Anderson W, Howes C, Heliotis M, Mantalaris A, Tsiridis E, Tsapakis E (2011) Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 10(4):575–602

Grant WB (2010) Low vitamin D may explain the link between preeclampsia and cardiovascular disease. Am Heart J 159(3):e19

Holmes VA, Barnes MS, Alexander HD, McFaul P, Wallace JM (2009) Vitamin D deficiency and insufficiency in pregnant women: a longitudinal study. Br J Nutr 102(6):876–881

Jiang HK, Wang JY (1998) Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. J Formos Med Assoc 97(12):830–837

Kilzieh N. Principal investigator. ClinicalTrials.gov Identifier: NCT00512070

Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59:123–129

Kristo C, Godang K, Ueland T, Lien E, Aukrust P, Froland SS, Bollerslev J (2002) Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing’s syndrome. Eur J Endocrinol 146(3):389–395

Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC (in press) Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull

Lanoix D, Beghdadi H, Lafond J, Vaillancourt C (2008) Human placental trophoblasts synthesize melatonin and express its receptors. J Pineal Res 45(1):50–60

Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR (2010) Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 210(1):84–91

Lee YD, Kim JY, Lee KH, Kwak YJ, Lee SK, Kim OS, Song DY, Lee JH, Baik TK, Kim BJ, Kim JY, Baik HW (2009) Melatonin attenuates lipopolysaccharide-induced acute lung inflammation in sleep-deprived mice. J Pineal Res 46(1):53–57

Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ (2011) Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 16(4):611

Lerner V, Miodownik C (2011) Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep 13(4):295–304

Luchowska E, Kloc R, Olajossy B, Wnuk S, Wielosz M, Owe-Larsson B, Urbanska EM (2009) Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatry 33(3):519–529

Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89:346–351

Maldonado MD, Pérez-San-Gregorio MA, Reiter RJ (2009a) The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CNS Drug Discov 4(1):61–69

Maldonado MD, Reiter RJ, Pérez-San-Gregorio MA (2009b) Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol 24(5):391–400

Mann K, Rossbach W, Müller MJ, Müller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C (2006) Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31(2):256–264

Marczynski TJ, Yamaguchi N, Ling GM, Grodzinska L (1964) Sleep induced by the administration of melatonin (5-methoxyn-acetyltryptamine) to the hypothalamus in unrestrained cats. Experientia 20(8):435–437

Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D (2002) Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 34(4):348–357

Marzullo G, Fraser FC (2009) Conception season and cerebral asymmetries among American baseball players: implications for the seasonal birth effect in schizophrenia. Psychiatry Res 167(3):287–293

McGrath J, Eyles D, Mowry B, Yolken R, Buka S (2003) Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res 63(1–2):73–78

Meyer U, Feldon J, Dammann O (2011) Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 69(5 Pt 2):26R–33R

Miller J, Gallo RL (2010) Vitamin D and innate immunity. Dermatol Ther 23(1):13–22

Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073–1074:25–37

Miller CL, Murakami P, Ruczinski I, Ross RG, Sinkus M, Sullivan B, Leonard S (2009) Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res 113(2–3):259–267

Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671

Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ (1992) Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res 7(1):77–84

Monteleone P, Natale M, La Rocca A, Maj M (1997) Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 36(4):159–163

Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. Brain Behav Immun 25(8):1576–1581

Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW (2009) Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 47(1):82–96

Park HJ, Park JK, Kim SK, Cho AR, Kim JW, Yim SV, Chung JH (2011) Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 45(2):304–308

Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808

Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH (2008) Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 65(9):1072–1078

Proietti S, Cucina A, D’Anselmi F, Dinicola S, Pasqualato A, Lisi E, Bizzarri M (2011) Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 50(2):150–158

Quiros I, Mayo JC, Garcia-Suarez O, Hevia D, Martin V, Rodríguez C, Sainz RM (2008) Melatonin prevents the glucocorticoid receptor inhibition of cell proliferation and toxicity in hippocampal cells by reducing the glucocorticoid receptor nuclear translocation. J Steroid Biochem Mol Biol 110:116–124

Rao ML, Gross G, Strebel B, Halaris A, Huber G, Bräunig P, Marler M (1994) Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 35(3):151–163

Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD (2007) Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 32(2):284–288

Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, Di Nicola M, Grilli A (2011) Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 25:12–13

Rennie K, De Butte M, Pappas BA (2009) Melatonin promotes neurogenesis in dentate gyrus in the pinealectomized rat. J Pineal Res 47(4):313–317

Reynolds RM, Walker BR, Phillips DI, Dennison EM, Fraser R, Mackenzie SM, Davies E, Connell JM (2009) Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure. Hypertension 53(6):932–936

Rimmele U, Spillmann M, Bärtschi C, Wolf OT, Weber CS, Ehlert U, Wirtz PH (2009) Melatonin improves memory acquisition under stress independent of stress hormone release. Psychopharmacology (Berl) 202(4):663–672

Sandyk R, Kay SR (1991) The relationship of pineal calcification to cortical atrophy in schizophrenia. Int J Neurosci 57(3–4):179–191

Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, Scherrer U, Duplain H (2009) Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 150(12):5311–5317

Schneider B, Weber B, Frensch A, Stein J, Fritz J (2000) Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm 107(7):839–842

Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A (2000) Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 61(8):556–558

Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R (2001) Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 58(11):1049–1052

Shieh JM (2009) Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK-3b pathway in hepatic cells. J Pineal Res 47(4):339–344

Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, Shenkman L (2000) Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 17(1):71–76

Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM (2007) Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 68(2):237–241

Tajes M, Gutierrez-Cuesta J, Ortuño-Sahagun D, Camins A, Pallàs M (2009) Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J Pineal Res 47(3):228–237

Tardieu S, Micallef J, Gentile S, Blin O (2003) Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 4(3):129–138

Utsunomiya K, Shinkai T, Sakata S, Yamada K, Chen HI, De Luca V, Hwang R, Ohmori O, Nakamura J (2012) Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations. Neurosci Lett 507(1):52–56

VIgano D, Lissoni P, Rovelli F, Roselli MG, Malugani F, Gavazzeni C, Conti A, Maestroni G (2001) A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuro Endocrinol Lett 22(2):137–141

Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY (2012) Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 37(1):106–110

Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A (2009) PGC-1alpha and PGC-1beta regulate mitochondrial density in neurons. J Biol Chem 284(32):21379–21385

Watson PE, McDonald BW (2007) Seasonal variation of nutrient intake in pregnancy: effects on infant measures and possible influence on diseases related to season of birth. Eur J Clin Nutr 61(11):1271–1280

Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM (2012) Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 200(4):308–316

Zhang L, Su P, Xu C, Chen C, Liang A, Du K, Peng Y, Huang D (2010) Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression. J Pineal Res 49(4):364–372

Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK (2005) The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25(18):4493–4502